Arecor Therapeutics PLC (FWB:6UI) Financings
Financings
| Raise | Date | In US dollars |
|---|---|---|
| New ordinary shares (Retail Offer Shares) Closed: £130,000 raised · GBX 68 a share · Singer Capital Markets +1 Dealers: Singer Capital Markets (lead), Singer Capital Markets Securities Limited Use of proceeds: General working capital and to strengthen the Group's balance sheet | Oct 7, 2026 | US$171,735 |
| Private placement of new ordinary shares Update: about £5M · GBX 68 a share · Singer Capital Markets Dealers: Singer Capital Markets (lead) Use of proceeds: Strengthen balance sheet, extend cash runway to December 2027 and fund critical-path insulin development activities | Sep 30, 2026 | US$6.61M |
| Royalty financing with warrants over ordinary shares Announced: up to US$11M · Warrants at GBX 67.39 for 120 months Buyers: Ligand Pharmaceuticals Inc. (royalty financing of up to $11 million; warrants over 1,002,739 ordinary shares); Ligand (pays up to $11.0 million for royalty and fee rights and receives warrants over 1,002,739 ordinary shares); Ligand Pharmaceuticals Incorporated (pays up to $11.0 million for royalty rights and receives warrants over 1,002,739 ordinary shares) Use of proceeds: Start AT278 Phase 2-enabling activities and extend cash runway to 1H 2027 | Sep 25, 2025 |